|
|
 |
DYADIC APPROVED FOR LISTING ON THE AMERICAN STOCK EXCHANGE
May 17, 2005
Dyadic International, Inc - http://www.dyadic-group.com
Alexander (Sasha) Bondar, (561)743-8333, sbondar@dyadic-group.com
JUPITER, Fla. Ü (via Business Wire) Ü Dyadic International, Inc. (OTCBB: DYAD), a biotechnology
company, today announced that it has been approved for listing on the American Stock Exchange ("Amex"). Dyadic's
common stock is expected to begin trading on the Amex under the ticker symbol "DIL" on May 26, 2005.
"We believe that our listing on the American Stock Exchange will increase the interest in our common stock and result
in greater visibility within the investment community," said Mark Emalfarb, Dyadic's Chief Executive Officer. "In addition,
a listing on a national exchange should further enhance our credibility with both existing and new partners and customers,
as we seek to expand our reach into new markets.æ Equipped with a wealth of new gene information coming from the recent
sequencing of Dyadic's proprietary C1 fungal genome, a strong balance sheet and an experienced team in place to advance
Dyadic's C1 Host Technology we have spent more than a decade developing, Dyadic is well positioned for future growth."
The Company's American Stock Exchange Specialist will be Weiskopf, Silver & Co.
The approval of the listing of Dyadic's common stock on the Amex is contingent upon Dyadic being in compliance with all
applicable listing standards on the date it begins trading on the Amex, and may be rescinded if the company is not in
compliance with such standards.
About Dyadic:
Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes,
peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators
for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services
for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using
its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production
of biological products.
Cautionary Statement for Forward-Looking Statements:
Statements contained in this press release may contain information that includes or is based upon certain "forward-looking
statements" relating to our business. For a discussion of the factors that could cause actual results to vary from these
forward-looking statements, please see our filings from time to time with the Securities and Exchange Commission, which
are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2004, which was filed with the SEC on April 15, 2005, and our Quarterly Report on Form
10-QSB, which was filed on May 17, 2005. We expressly disclaim any intent or obligation to update any forward-looking
statements.
|
|
